Senior Director, Associate General Counsel, Launch Readiness and Commercial Execution, Europe
Revolution Medicines
| Company | Revolution Medicines |
| Category | Legal & Compliance |
| Location | Basel |
| Remote | On-site (inferred) |
| Employment | Not stated |
| Level | Director |
| Salary | Not stated by the employer |
| Posted | 22 Jul 2026 |
| Last verified | 12 Aug 2026 |
| Source | Employer ATS (greenhouse) |
Description
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity:
Revolution Medicines is seeking an experienced and business-oriented Senior Attorney to support our European Commercial Organisation’s rapid build out and scale up to the European Launch of Daraxonrasib and beyond. This highly strategic leadersip position will focus on managing and leading local attorneys in 5 key markets, forming a Business Partnering relationship with the in-market GMs and the regional head, drafting and negotiating a broad range of commercial agreements, with particular emphasis initially on Market Access, Early Access Programmes and Launch Readiness.
The critical role will also support commercialization readiness for initial European and other product launches, including review of promotional, medical education and disease awareness materials in accordance with applicable EU and national laws, EMA guidance, EFPIA and national industry codes and internal policies as well as general support across the European Legal team as business needs evolve.
The ideal candidate will bring excellent leadership, commercial contracting, launch preparation and market access experience within the biotechnology, pharmaceutical or life sciences industry and demonstrate sound judgment, pragmatism and the ability to operate effectively and at times independently in a fast-paced, collaborative environment.
This is a unique opportunity to play a pivotal role in bringing an innovative oncology medicine to patients across Europe. You will join a growing, mission-driven biotechnology company at a defining stage in its evolution, partnering with exceptional colleagues and helping build the legal foundations for long-term commercial success.
As a key senior member of the European Legal Team, you will have significant visibility, influence and the opportunity to shape both the European legal function and the company's launch strategy during a transformational period of growth
The successful candidate will demonstrate:
Strategic thinking and strong business acumen.
Proven ability to lead through complexity and rapid organisational change.
Collaborative and inclusive leadership style.
Sound judgement and integrity.
Resilience and adaptability in a dynamic environment.
Ability to make risk-based decisions while enabling business objectives.
Passion for developing people and building high-performing teams.
Key Responsibilities will include:
European Launch Readiness
Lead legal support for European launch readiness activities for the company's first oncology product.
Develop and execute the European legal launch strategy in partnership with cross-functional leadership.
Identify legal risks that may impact launch timelines and develop pragmatic mitigation strategies.
Support launch governance and serve as a senior legal representative on European launch teams.
Coordinate legal support across headquarters, regional and local teams to ensure consistent execution.
Commercialisation
Act as a k